Starpharma share price races 6% higher on clinical trials update

The Starpharma Holdings Limited (ASX:SPL) share price has raced 6% higher following a positive update on its ongoing clinical trials…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has been amongst the best performers on the All Ordinaries index on Wednesday.

In morning trade the dendrimer products developer's shares raced as much as 6% higher to $1.21 following the release of a positive update.

What did Starpharma announce?

This morning Starpharma announced that promising efficacy signals have been observed in its ongoing clinical trials for both DEP cabazitaxel and DEP docetaxel.

DEP cabazitaxel and DEP docetaxel are two of three clinical stage products from Starpharma's DEP platform, alongside DEP irinotecan.

DEP cabazitaxel.

The DEP cabazitaxel product is a patented, detergent free version of the cancer drug, Jevtana, and is currently in a phase 1/2 trial.

According to the release, efficacy signals in the DEP cabazitaxel trial have been seen in "several patients with a variety of tumour types where stable disease of more than 30 weeks, and a decrease in specific tumour biomarkers such as PSA, have been observed."

This includes in prostate cancer for which Jevtana is approved, and also others such as pancreatic and ovarian cancers, which are not currently approved indications for Jevtana.

Another positive was patients that were treated with DEP cabazitaxel exhibited a notable lack of bone marrow toxicity compared to Jevtana. This is great news as greater than 90% of patients experience these potentially life-threatening bone marrow toxicities with Jevtana.

DEP docetaxel.

DEP docetaxel is a patented, detergent-free, enhanced version of the widely used anticancer drug, docetaxel (Taxotere), and is currently in a phase 2 trial.

The release advises that this product is also delivering promising interim results in prostate cancer, non-small cell lung cancer (NSCLC), and in tumour types not typically treated with docetaxel.

The DEP docetaxel phase 2 program includes both a monotherapy arm and the use of the product in combination with Nintedanib. Both arms continue to show a notable lack of bone marrow toxicity and other common side effects including hair-loss, anaphylaxis and oedema.

The company's CEO, Dr Jackie Fairley, said: "We are very pleased with these early observations for DEP cabazitaxel, particularly for those patients who have had longstanding stable disease and reduced bone marrow toxicity which often results in significant side-effects (neutropenia, anaemia etc) with Jevtana therapy. In addition, the fact that we are seeing efficacy in a variety of tumours such as prostate, pancreatic and ovarian is extremely promising."

"The growing body of clinical data from our DEP docetaxel and DEP cabazitaxel products demonstrates the compelling advantages for patients and for our commercial partners. The commercial utility of the DEP platform is also evidenced by our partnerships, including with AstraZeneca, and we look forward to them taking their first DEP candidate, AZD0466, into the clinic later this year," added Dr Fairley.

Also on the rise in the industry today are the Opthea Ltd (ASX: OPT) share price following a broker upgrade and the Auscann Group Holdings Ltd (ASX: AC8) share price on the back of no news.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »